Promoting natural killer cell functions by recombinant immunoligands mimicking an induced self phenotype

OncoImmunology

Volumn 2, Issue 6, 2013, Pages

  Kellner, Christian ^a   Gramatzki, Martin ^a   Peipp, Matthias ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

ADCC; Antibody; NK cells; NKG2D; NKp30

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD20 ANTIGEN; CD33 ANTIGEN; DARATUMUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SYNDECAN 1; TRANSFORMING GROWTH FACTOR BETA;

ADAPTIVE IMMUNITY; ANTIBODY DEPENDENT LYMPHOCYTOTOXICITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL FUNCTION; CYTOKINE PRODUCTION; DOWN REGULATION; HOST CELL; IMMUNOREACTIVITY; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; MOLECULAR RECOGNITION; NATURAL KILLER CELL; NONHUMAN; PHENOTYPIC VARIATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR ESCAPE; UPREGULATION;

EID: 84886944525     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.24481     Document Type: Article

References (10)

1. Raulet DH, Guerra N. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol 2009; 9:568-80; PMID:19629084; http://dx.doi.org/10.1038/nri2604
2. Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene 2008; 27:5944-58; PMID:18836475; http://dx.doi.org/10.1038/onc.2008.272
3. von Strandmann EP, Hansen HP, Reiners KS, Schnell R, Borchmann P, Merkert S, et al. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 2006; 107:1955-62; PMID:16210338; http://dx.doi. org/10.1182/blood-2005-05-2177
4. Jachimowicz RD, Fracasso G, Yazaki PJ, Power BE, Borchmann P, Engert A, et al. Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma. Mol Cancer Ther 2011; 10:1036-45; PMID:21525185; http://dx.doi. org/10.1158/1535-7163.MCT-10-1093
5. Germain C, Larbouret C, Cesson V, Donda A, Held W, Mach JP, et al. MHC class I-related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cells. Clin Cancer Res 2005; 11:7516-22; PMID:16243826; http://dx.doi. org/10.1158/1078-0432.CCR-05-0872
6. Stamova S, Cartellieri M, Feldmann A, Bippes CC, Bartsch H, Wehner R, et al. Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells. Leukemia 2011; 25:1053-6; PMID:21415850; http://dx.doi.org/10.1038/leu.2011.42
7. Kellner C, Hallack D, Glorius P, Staudinger M, Mohseni Nodehi S, de Weers M, et al. Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity. Leukemia 2012; 26:830-4; PMID:22005785; http://dx.doi. org/10.1038/leu.2011.288
8. Vivier E, Nunès JA, Vély F. Natural killer cell signaling pathways. Science 2004; 306:1517-9; PMID:15567854; http://dx.doi.org/10.1126/science. 1103478
9. Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B, et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 2009; 206:1495-503; PMID:19528259; http://dx.doi.org/10.1084/jem.20090681
10. Kellner C, Maurer T, Hallack D, Repp R, van de Winkel JG, Parren PW, et al. Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity. J Immunol 2012; 189:5037-46; PMID:23066150; http://dx.doi.org/10.4049/jimmunol.1201321